Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

The investment is expected to help enhance the company temperature-controlled services in the Netherlands, France, Italy, and Hungary.

UPS Healthcare Financially Commits Over $21.6 Million Toward Cold Chain Fleet

The Stelara biosimilar will be commercialized by Sandoz, and is expected to launch by February 2025 for multiple indications, including for the treatment of adult patients with active psoriatic arthritis.

FDA Approves Pyzchiva for Use in the United States

The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product. 

 Genezen Purchases uniQure’s Gene Therapy Operations in Massachusetts

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform. 

Kite to Assess Cellares’ Automated Manufacturing Platform

The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.

Veranova Expands Its Financial Commitment Toward Growing Highly Potent API Services

The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.

Novo Nordisk Financially Commits $4.1 Billion Toward Growing US Manufacturing Capabilities

The company acquires Alimera Sciences for $381 million upfront, while establishing its interest in ophthalmology.

ANI Pharmaceuticals Expands Rare Disease Offerings

Podcasts

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

Navigating Market Access Hurdles

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

Bora Pharmaceuticals to Purchase Emergent’s Sterile Manufacturing Facility 

Deal will target neurological diseases, featuring an initial payment of $42 million for Ascidian and up to $1.8 billion in milestone payments/royalties.

Business and Finance